

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2021.354	10/05/2024	19/05/2024
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
ACADEMIC DEGREE	• PhD.	
VALUED MERITS / SKYLLS		
TRAINING	<ul style="list-style-type: none"> • Research training • Bioinformatics training. • Project management training 	
EXPERIENCE	<ul style="list-style-type: none"> • Experience in design and implementation of research projects. • Experience working in multidisciplinary preclinical research groups. • Experience advising and contributing to the training of the group's technical personnel. • Development of research projects in Cancer. 	
LANGUAGES	• English (<i>Certificates or diplomas must be provided</i>).	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
Contract for scientific-technical activities (article 23.bis of Law 14/2011, of June 1, on Science, Technology and Innovation)	September 2024	Full time. 1575 hours per year (aprox. 35 h/week)
ANNUAL GROSS SALARY	DURATION OF THE CONTRACT	
30.926,81 € without prejudice to the basic update established in state legislation for 2024.	Indefinite (linked to the duration of the project or to external financing or financing from public grants in full competition).	
WORK LOCATIONS	UNIT/DEPARTMENT	
IDIVAL	Hematology Service (HUMV-IDIVAL)	
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
<ul style="list-style-type: none"> • Design and writing of projects. • Writing of manuscripts in English. • Analysis of new drugs in the preclinical phase. Assessment of toxicities and dose adjustment • Analysis of results. • Development of protocols for the administration and management of the research product. • Communication with the national and international team for the development of projects. 		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Enrique M. Ocio	Hematologic neoplasms and hematopoietic progenitor transplantation.	Randomized phase III study comparing bortezomib, lenalidomide, and dexamethasone (VRd) followed by ciltacabtagene autoleucel, a chimeric antigen receptor T-cell (T-CAR) therapy directed against BCMA vs. bortezomib, lenalidomide and dexamethasone (VRd) followed by lenalidomide and dexamethasone (Rd) therapy in newly diagnosed patients with multiple myeloma



		for whom hematopoietic stem cell transplantation is not planned as initial treatment.		
RECRUITMENT INFORMATION				
SELECTION PROCESS STAGES (2)				EMPLOYMENT EXCHANGE
1. Admission of applications. 2. Competition phase. 3. Interview phase: maximum number of candidates to be interviewed: 2. Minimum score for this phase: 40 4. Report of the Tribunal. 5. Resolution. Note: in order for candidates to be considered for recruitment and employment exchange purposes, they must have a total score of at least 30 points.				NOT
SELECTION BOARD				
<ul style="list-style-type: none"> President: Enrique M. Ocío San Miguel, Head of Hematology Department at HUMV. Member: Patricia Maiso, Research Scientist at IDIVAL. Member and secretary: Maria José Marín Vidalled, Coordinator of IDIVAL's Technological Services). 				
VALUATION OF MERITS				
MERITS	EVALUATION	SCORE		MAXIMUM
Experience in design and implementation of research projects.	CV	Compliance	YES/NOT	10
Experience working in multidisciplinary preclinical research groups.	CV	Compliance	YES/NOT	10
Experience advising and contributing to the training of the group's technical personnel.	CV	Compliance	YES/NOT	10
Participation in translational research projects in Cancer.	CV	Compliance	YES/NOT	5
Research training	CV	Compliance	YES/NOT	5
Training in bioinformatics	CV	Compliance	YES/NOT	5
Training in project management	CV	Compliance	YES/NOT	5
English	Acreditación	Level	B2:3 POINTS C1:5 POINTS	5
FINAL SCORE				
MAXIMUM TOTAL SCORE BY MERITS				60
MAXIMUM TOTAL SCORE IN INTERVIEW				40
MAXIMUM TOTAL SCORE				100

- (1) Not subsanable
 (2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Politica-de-Privacidad

Santander as of the date of electronic signature



Fdo. Francisco Galo Peralta Fernandez

Código seguro de Verificación : GEN-ab28-682a-adb5-cac5-82df-e2f6-3cc5-f6f0 | Puede verificar la integridad de este documento en la siguiente dirección : <https://portafirmas.redsara.es/pf/valida>

Av. Cardenal Herrera Oria s/n | www.idival.org
39011 Santander - España | Tel. +34 942 31 55 15

Fundación Instituto de Investigación Marqués de Valdecilla
CIF: G 39788773

CSV : GEN-ab28-682a-adb5-cac5-82df-e2f6-3cc5-f6f0

DIRECCIÓN DE VALIDACIÓN : <https://portafirmas.redsara.es/pf/valida>

FIRMANTE(1) : FRANCISCO GALO PERALTA FERNANDEZ | FECHA : 09/05/2024 12:41 | Sin acción específica

